Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 7/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7117234 | 0.84 | CTNNB1 (0.36) | MMP13TP53 | |
| SCHEMBL7116976 | 0.83 | MMP2 (0.30) | MMP13 | |
| SCHEMBL7545020 | 0.82 | GRM2 (0.40) | SMN1; SMN2GRM2ADAMTS4LMNATP53 | |
| SCHEMBL7545007 | 0.82 | GRM2 (0.40) | SMN1; SMN2GRM2ADAMTS4LMNATP53 | |
| SCHEMBL7545000 | 0.82 | GRM2 (0.40) | SMN1; SMN2GRM2ADAMTS4LMNATP53 | |
| SCHEMBL7127966 | 0.81 | ATM (0.35) | MMP13TP53 | |
| SCHEMBL7115873 | 0.81 | MMP2 (0.40) | SMN1; SMN2GRM2MMP13ADAMTS4LMNA | |
| SCHEMBL7115876 | 0.81 | MMP2 (0.40) | SMN1; SMN2GRM2MMP13ADAMTS4LMNA | |
| SCHEMBL7115880 | 0.81 | MMP2 (0.40) | SMN1; SMN2GRM2MMP13ADAMTS4LMNA | |
| SCHEMBL7114239 | 0.78 | MMP2 (0.35) | MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030134880-A1 | Novel cd23 inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134880-A1 | Novel cd23 inhibitors | CD2, CD22, CD40 | SMN1; SMN2 3194/4885GRM2 1948/4885MMP13 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.